Paul Wylie

Director
Abcam, United Kingdom

Paul completed his PhD At the University of Leicester researching GPCR signaling of MAP kinase pathways. Having worked in screening groups at Pfizer and Knoll, he then joined TTP Labtech, a company which developed and sold a high throughput high content imager for screening phenotypic assays. Here he ran the Assay Development and Field Applications team, working with reagent vendors and customers to develop high throughput imaging assays for many of the world’s largest pharma companies, including in 1536 well formats. At Abcam, Paul is now Director of Multiplex and is responsible for developing and delivering Abcam’s multiplex product strategy with a particular focus on novel biomarker screening solutions. h scientists to understand their problems and requirements to help to provide robust multiplexed assay solutions.

Disclosure information not submitted.

Presentation(s):

• Abcam Exhibitor Tutorial: Enabling multiplexed Biomarker Discovery and Screening immunoassays with FirePlex®

  Tuesday, February 8, 2022
  11:30 AM – 12:30 PM